Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company demonstrated strong financial performance and optimistic guidance, with record high revenue and EBITDA, and a strategic focus on high-margin products and disciplined execution. New product launches and improvements in EBITDA margins are planned. Despite some concerns about limited float, the company is committed to resolving it. The Q&A highlighted confidence in market positioning and growth strategies, further supporting a positive outlook. Overall, these factors suggest a likely positive stock price movement over the next two weeks.
Key Financial Performance
Revenue (Q4 2025) $1.4 billion, up 7% year-over-year. Growth attributed to strong performance across all segments and a $37 million currency tailwind.
Adjusted EBITDA (Q4 2025) $330 million, up 27% year-over-year. Growth driven by operating leverage and cost structure improvements.
Adjusted EBITDA Margin (Q4 2025) 23.5%, up 330 basis points year-over-year. Reflects improved operating efficiencies.
Full Year Revenue (2025) $5.101 billion, up 5% year-over-year (6% excluding enVista recall). Growth across all segments and a $58 million currency tailwind.
Vision Care Revenue (Q4 2025) $778 million, up 5% year-over-year. Growth driven by consumer and contact lenses, including LUMIFY and Blink.
LUMIFY Revenue (Q4 2025) $63 million, up 24% year-over-year. Full year revenue was $221 million, up 16%.
Consumer Dry Eye Portfolio Revenue (Q4 2025) $116 million, up 6% year-over-year. Growth led by Blink, which grew 33%.
Contact Lens Revenue (Q4 2025) Up 8% year-over-year. Growth led by DD SiHy (up 17%) and Ultra (up 16%).
Surgical Segment Revenue (Q4 2025) $249 million, up 3% year-over-year (6% excluding enVista recall). Growth driven by Implantables (up 5%) and Premium IOLs (up 20%).
Pharma Segment Revenue (Q4 2025) $378 million, up 14% year-over-year. Growth led by Miebo (up 111%) and Xiidra.
Miebo Revenue (Q4 2025) $112 million, up 111% year-over-year. Full year revenue was $316 million, up 84%.
Adjusted Gross Margin (Q4 2025) 62.1%, absorbing an 80 basis point impact from tariffs.
Adjusted R&D Investment (Q4 2025) $94 million, in line with Q4 2024. Full year R&D was $371 million, up 8%.
Adjusted Cash Flow from Operations (Q4 2025) $152 million. Full year adjusted cash flow was $381 million.
Adjusted Free Cash Flow (Q4 2025) $76 million. Full year adjusted free cash flow was $32 million.
Net Interest Expense (Q4 2025) $95 million. Full year net interest expense was $376 million, excluding a $33 million refinancing fee.
Adjusted Tax Rate (2025) 10%, lower than the previous guidance of 15%, driven by the enVista recall and other onetime adjustments.
Adjusted EPS (Q4 2025) $0.32, including a $0.08 noncash charge. Excluding the charge, EPS was $0.40.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Miebo: Generated $112 million in Q4 revenue, with a trajectory towards profitability as it exits the launch phase. Expected peak sales now exceed $600 million.
PreserVision AREDS3: Started shipping on February 2, targeting earlier patient engagement in AMD care.
Blink Triple Care preservative-free: Expected to ship on March 1, building on 38% revenue growth in 2025.
Daily SiHy multifocal lenses: Launched in several European countries, Korea, and New Zealand in early 2026.
Dry eye market: Global market expected to double in the next 4 years, driven by aging population, environmental factors, and increased screen time.
China Contact Lens market: Grew 7% in Q4 and 8% for the full year despite consumer softness.
Adjusted EBITDA growth: Achieved 27% growth year-over-year in Q4, with a margin of 23.5%.
Revenue growth: Total company revenue grew 7% in Q4 and 6% for the full year, excluding the enVista recall.
Margin expansion: Adjusted EBITDA margin expanded to 23.5% in Q4, with steady improvement throughout the year.
Pipeline development: CE mark submission for seeLYRA laser expected soon, with approval anticipated in the second half of 2026. New bioactive contact lens material study met expectations, with a second study planned for 2028 launch.
Surgical business: Strategic moves in Q4 positioned for margin improvement, with Premium IOL portfolio driving 20% revenue growth in Q4.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Seasonality in Business: The company acknowledges that seasonality, especially in the Pharmaceutical segment, could impact revenue and operational performance, potentially leading to fluctuations in financial results.
Impact of enVista Recall: The enVista recall had a significant impact on revenue growth in the Surgical segment, although the company has made progress in recovering from this issue.
Currency Fluctuations: Currency fluctuations were noted as a factor affecting revenue, with both positive and negative impacts depending on the quarter.
Debt and Interest Expense: The company faces significant interest expenses, with $376 million in 2025, which could impact profitability and cash flow.
Consumer Softness in China: While the Contact Lens business in China grew, there is some consumer softness in the region, which could pose challenges to sustained growth.
Regulatory Approvals: The company is awaiting regulatory approvals for products like seeLYRA, which could delay launches and impact revenue projections.
Market Competition in Dry Eye Segment: The dry eye market is growing, but competitive pressures could impact the performance of flagship products like Miebo and Xiidra.
Supply Chain and Tariffs: Tariffs impacted adjusted gross margin by approximately 80 basis points, indicating potential supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For 2026, the company expects full-year revenue to be in the range of $5.375 billion to $5.475 billion, representing constant currency growth of 5% to 7%. Currency tailwinds are estimated to contribute approximately $30 million to revenue.
Adjusted EBITDA: The company projects adjusted EBITDA in the range of $1 billion to $1.050 billion, reflecting a margin of approximately 19% at the midpoint and adjusted EBITDA growth of approximately 15% year-over-year.
Adjusted Gross Margin: Expected to be approximately 62% for 2026.
R&D Investments: Planned investments in R&D are expected to be in the range of 7.5% to 8% of revenue for 2026.
CapEx: Full-year capital expenditures are projected to be approximately $285 million.
Tax Rate: The adjusted tax rate for 2026 is expected to be approximately 19%.
Seasonality: The company anticipates natural seasonality in its business, with the first quarter being the lowest and the fourth quarter being the highest, particularly as the dry eye franchise continues to grow.
Dry Eye Medications: Miebo peak sales are now expected to exceed $600 million, up from the previous estimate of $500 million. Xiidra and Miebo are anticipated to contribute significantly to revenue growth and profitability in 2026.
Market Trends: The global dry eye market is expected to nearly double in the next four years, driven by factors such as an aging population, environmental changes, and increased screen time.
Product Launches: PreserVision AREDS3 and Blink Triple Care preservative-free are set to launch in early 2026. CE mark submission for seeLYRA, a next-generation femtosecond laser, is expected soon, with approval anticipated in the second half of the year.
Pipeline Developments: The company is on track for a 2028 launch of its new bioactive contact lens material, with ongoing trials and improvements underway.
Surgical Segment: Momentum in the Surgical segment is expected to continue, with premium IOL offerings driving growth and new options being introduced globally.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company planning to achieve growth in 2026, and what are the key areas of focus?
A:The company plans to achieve growth in 2026 by focusing on disciplined execution, as demonstrated by their Q4 2025 results, which showed 7% growth and the highest revenue and EBITDA in the company's history. They are leveraging their Vision 27 program, which includes shifting to higher-margin products, improving pricing discipline, driving productivity, and operating with a more fixed cost infrastructure. The company believes their foundational changes and cultural shift towards execution will drive long-term value.
Q:What lessons has the company learned from the success of Miebo, and how will these lessons be applied to the pipeline?
A:The success of Miebo, which exceeded $600 million in sales, was attributed to upgrading the team, making strategic investments, and leveraging its strong benefit-risk profile. The company plans to apply these lessons, such as best-in-class field force execution and strategic marketing, to future pipeline products to replicate this success.
Q:What is the growth trajectory for Miebo, and how does seasonality impact its performance?
A:Miebo is expected to continue strong growth, with seasonality playing a significant role. Q1 is typically the softest quarter due to copays and deductibles, while Q4 is the strongest. The company has built infrastructure around the dry eye franchise and achieved nearly 4 out of 5 patient access for both commercial and Medicare, which supports its growth trajectory.
Q:How does the company view the competitive landscape in 2026, and which segments face the toughest challenges?
A:The company takes all competition seriously and feels well-positioned in the pharmaceutical, contact lens, and surgical markets. They have strong products and execution in the dry eye market, are growing faster than the market in contact lenses, and are launching new products in the surgical segment. The surgical market is considered the most competitive, but the company is confident in its ability to grow faster than the market in all three segments.
Q:What progress has been made on the new material for contact lenses, and what are the next steps?
A:The company completed the first clinical evaluation of their Halo daily disposable contact lens, which showed very good visual acuity in 98.5% of participants and no adverse events. They are analyzing the data to optimize the lens design for the next external study, targeting a 2028 launch.
Q:What is the company's approach to EBITDA margin improvement in 2026, and what are the key drivers?
A:The company aims to improve EBITDA margin to 19% in 2026, driven by 100 basis points improvement in gross margin, 100 basis points improvement in SG&A leverage, and a 50 basis points increase in R&D investment. They are focused on financial excellence, leveraging fixed cost structures, and targeted investments to achieve this goal.
Q:What is the outlook for Xiidra in 2026, and how will pricing and volume dynamics play out?
A:Xiidra is expected to achieve mid-single-digit sales growth in 2026, with slower TRx growth but higher net revenue due to improved pricing. The company has strong coverage rates and is balancing affordability with long-term investment.
Q:What is the company's strategy for the consumer business, and how will innovation drive growth?
A:The consumer business grew 5% in 2025, with strong performance from LUMIFY (up 16%) and Blink (up 14%). The company is launching new products like LUMIFY Lux and AREDS3 to drive growth. AREDS3 is expected to revive the PreserVision category, which has seen limited growth due to a lack of innovation.
Q:What is the company's free cash flow outlook for 2026, and what are the key factors?
A:The company expects free cash flow conversion to improve to about 45% in 2026, supported by reduced CapEx (5-6% of revenue) and continued operational improvements. They achieved 42% conversion in 2025 and are targeting 50% by 2028.
Q:What is the company's response to concerns about the limited float and its impact on valuation?
A:The company acknowledges that the limited float is a concern for investors and agrees it needs to be resolved. However, the decision lies with Bausch Health Companies (BHC), which has indicated plans to sell shares in time. The company remains focused on operational execution and delivering results.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct timeline or specific details regarding the resolution of the limited float issue, stating that it is a decision for Bausch Health Companies (BHC).
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Consumer eye
Contact Lens
Generics basis
Global Pharmaceuticals
Implantables
International Consumer
Investor Day
Miebo Xiidra
Miebo prescription
Pharmaceuticals International
PreserVision
President Global
Slides
cash flow
commitment excellence
counter
discipline
generation
level
leverage
margin expansion
margin improvement
market access
midpoint
opportunity eye
path
peak sale
prescription therapy
professional patient
rate term
record
reference
study
tailwind
target
BLCO Transcript
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Positive2-18
The company demonstrated strong financial performance and optimistic guidance, with record high revenue and EBITDA, and a strategic focus on high-margin products and disciplined execution. New product launches and improvements in EBITDA margins are planned. Despite some concerns about limited float, the company is committed to resolving it. The Q&A highlighted confidence in market positioning and growth strategies, further supporting a positive outlook. Overall, these factors suggest a likely positive stock price movement over the next two weeks.
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
BLCO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
